4D Molecular Therapeutics, Inc. (FDMT) Return on equity 2020–2025
4D Molecular Therapeutics, Inc. (FDMT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-27.7%FY2025 · since FY2020: -22.1% → -27.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -27.7% | +3.8 pp |
| FY2024 | -31.5% | +1.3 pp |
| FY2023 | -32.8% | +13.7 pp |
| FY2022 | -46.5% | -24.1 pp |
| FY2021 | -22.3% | -0.2 pp |
| FY2020 | -22.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More FDMT financial trends
FDMT RevenueFDMT Net incomeFDMT Net marginFDMT Gross profitFDMT Gross marginFDMT Operating incomeFDMT Operating marginFDMT Operating cash flowFDMT Free cash flowFDMT Capital expendituresFDMT Stock buybacksFDMT Dividends paidFDMT Total assetsFDMT Total liabilitiesFDMT Shareholders’ equityFDMT overview →